Junevity, a San Francisco, CA-based biotechnology cell reset therapeutics company, raised $10M in seed funding.
The round was led by Goldcrest Capital and Godfrey Capital.
The company intends to use the funds to expand operations and its R&D efforts. Initial focus is Type 2 diabetes, obesity and frailty, with the potential to address numerous indications.
Co-founded by CEO Dr. John Hoekman, Ph.D., CSO Dr. Janine Sengstack, Ph.D. and COO Rob Cahill, Junevity is a biotechnology company developing cell reset therapeutics for longevity. Its RESET platform uses large-scale human data and AI to identify transcription factor targets and repress them with siRNA therapeutics. The company is creating siRNA therapeutics to address diseases collectively impacting billions of people worldwide, including Type 2 diabetes, obesity, frailty and more.
FinSMEs
13/02/2025